
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is positioned to potentially compete successfully in the market of anti-VEGF therapies for retinal diseases, with their drug TH103 showing promising results in clinical trials and potential for longer-lasting and increased anti-VEGF activity. However, they face competition from other companies also developing anti-VEGF drugs, and the need for additional funding to bring their product to market. The recent acquisition of Allergan by AbbVie highlights the importance of treatments for intraocular inflammation, which could also be a benefit for Kalaris Therapeutics as TH103 has shown minimal inflammation in their studies.
Bears say
Kalaris Therapeutics is a clinical-stage biopharmaceutical company with a potentially game-changing drug, TH103, in its pipeline for wet AMD treatment. With its unique mechanism of action and potential for longer-lasting VEGF suppression, TH103 has the potential to gain a significant market share in the $15B+ wet AMD industry upon its projected launch in 2032. However, it faces competition from other treatments in development, and its success will depend on its safety and efficacy compared to already established therapies like Lucentis and Eylea.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares